ECTRIMS 2017 Drug May Slow Conversion to Definite MS From Clinically Isolated Syndrome

Drug May Slow Conversion to Definite MS From Clinically Isolated Syndrome

Aubagio may cause delays in conversion to clinical definite MS by slowing the loss of cortical grey matter.

ECTRIMS 2017 Switch to Alemtuzumab Reduces MS Disease Activity

Switch to Alemtuzumab Reduces MS Disease Activity

Patients experienced reduced disease activity when switched to alemtuzumab.

ECTRIMS 2017 Disability Progression Slowed in Relapsing MS With Ocrelizumab Treatment

Disability Progression Slowed in Relapsing MS With Ocrelizumab Treatment

Data show superiority of OCREVUS compared to Rebif in reducing disability progression independent of relapse activity in people with RMS.

ECTRIMS 2017 Novel Multiple Sclerosis Drug Shows Promise

Novel Multiple Sclerosis Drug Shows Promise

Celgene announced new Phase 3 data evaluating the safety and efficacy of ozanimod vs Avonex for RMS.

ECTRIMS 2017 Fingolimod Promising for Pediatric Relapsing Multiple Sclerosis

Fingolimod Promising for Pediatric Relapsing Multiple Sclerosis

There are no FDA-approved MS therapies for the pediatric population.

ECTRIMS 2017 Comorbidities May Increase Relapse Risk in Multiple Sclerosis

Comorbidities May Increase Relapse Risk in Multiple Sclerosis

An emerging line of inquiry suggests a potential association between comorbidities and MS relapses, but studies have been limited.

ECTRIMS 2017 OSA Screening Advised for Fatigued Patients With MS

OSA Screening Advised for Fatigued Patients With MS

Patients with multiple sclerosis who experience severe fatigue should be screened for obstructive sleep apnea.

ECTRIMS 2017 Multiple Sclerosis Lesion Location Linked to Hyperalgesia, Hypoalgesia

Multiple Sclerosis Lesion Location Linked to Hyperalgesia, Hypoalgesia

In patients with multiple sclerosis, lesions in the right dorsolateral prefrontal cortex may be associated with hypoalgesia, and lesions in the posterior periventricular area, with hyperalgesia.

ECTRIMS 2017 Earlier Onset of Multiple Sclerosis Linked to Cesarean Delivery, Artificial Lactation

Earlier Onset of Multiple Sclerosis Linked to Cesarean Delivery, Artificial Lactation

Researchers believe that environmental factors may impact disease severity characteristics in genetically susceptible populations.

ECTRIMS 2017 Detecting Cognitive Decline in Multiple Sclerosis With Shortened BICAMS

Detecting Cognitive Decline in Multiple Sclerosis With Shortened BICAMS

With its 20-minute application time, the BICAMS is one of the few tools available for small centers with only a few staff members who might not be trained in administering neuropsychological tests.

Upcoming Meetings

Sign Up for Free e-newsletters